Physician profile
Jonathan Patrick Mcfadden
NPI 1083057418
$12,144.47
in general payments reported to CMS, 2019-2025
64 companies · $2,752 in 2025
The $2,752 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.30 · 2021: $1,516 · 2022: $2,023 · 2023: $2,514 · 2024: $3,258 · 2025: $2,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,454 · Education: $69.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,454.28 |
| Education | $69.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,688.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,418.60 | 2021-2025 | |
| Lilly USA, LLC | $1,071.65 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $741.08 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $716.20 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $678.09 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $671.14 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $449.89 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.59 | 2021-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $379.52 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.94 | 2022-2024 | |
| Exact Sciences Corporation | $325.36 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $320.36 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $282.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.90 | 2022-2024 | Trulance, Xifaxan, Cycloset |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $211.02 | 2023-2024 | Korlym |
| Radius Health, INC. | $173.90 | 2023-2025 | Tymlos |
| Dexcom, INC. | $136.42 | 2021-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $135.97 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $130.26 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $113.70 | 2021-2025 | Shingrix, Arexvy |
| Medtronic, INC. | $98.46 | 2024-2025 | Minimed 780g, Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $94.78 | 2022 | |
| Cequr Corporation | $92.23 | 2023-2025 | Cequr Simplicity |
| Medtronic Vascular, INC. | $82.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $79.71 | 2024-2025 | Voquezna |
| Amneal Pharmaceuticals LLC | $76.39 | 2025 | Unithroid |
| Actelion Pharmaceuticals US, INC. | $74.16 | 2024-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $70.96 | 2023-2025 | Nexletol |
| Sanofi Pasteur INC. | $64.79 | 2025 | |
| Qol Medical, LLC | $55.19 | 2023-2024 | Sucraid, Sucraid |
| Ascendis Pharma Endocrinology INC | $48.29 | 2025 | Yorvipath |
| Astellas Pharma US INC | $41.42 | 2021-2023 | Veozah |
| Axsome Therapeutics, INC. | $40.79 | 2024 | Auvelity |
| Edwards Lifesciences Corporation | $37.62 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $32.13 | 2023 | Quviviq |
| Ibsa Pharma INC. | $31.30 | 2021 | |
| Laborie Medical Technologies Corp. | $29.67 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Kowa Pharmaceuticals America, INC. | $27.67 | 2021 | |
| Boston Scientific Corporation | $27.66 | 2025 | Bodyguardian |
| Tempus Ai, INC | $25.73 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $23.81 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.73 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $22.57 | 2022 | |
| Sequel Med Tech, LLC | $21.70 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $20.02 | 2025 | Isturisa |
| Sumitomo Pharma America, INC. | $19.53 | 2024 | Gemtesa |
| Ascensia Diabetes Care US INC. | $19.17 | 2025 | |
| Lucid Diagnostics INC. | $18.69 | 2022 | |
| Dynavax Technologies Corporation | $18.04 | 2022 | |
| Teleflex LLC | $17.79 | 2023 | Urolift |
| Irhythm Technologies, INC. | $17.01 | 2024 | Zio Xt Patch, Zio Monitor |
| Zealand Pharma US, INC. | $16.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.73 | 2024 | Strensiq |
| Clarus Therapeutics INC. | $16.23 | 2021 | |
| Amryt Pharma Holdings LTD | $15.57 | 2023 | Mycapssa |
| Ars Pharmaceuticals Operations, INC. | $15.01 | 2025 | Neffy |
| Amphastar Pharmaceuticals, INC. | $14.77 | 2025 | |
| Kyowa Kirin, INC. | $14.58 | 2023 | Crysvita |
| Insulet Corporation | $14.51 | 2022 | |
| Shield Therapeutics INC | $14.29 | 2025 | |
| Endo Pharmaceuticals INC. | $14.05 | 2021 | |
| Chiesi USA, INC. | $13.21 | 2024 | Mycapssa |
| Procept Biorobotics Corporation | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.